Date Time
Major collaboration aims to eliminate cervical cancer in Western Pacific
Researchers at The Kirby Institute will collaborate on a first-of-its-kind program to set Papua New Guinea and Vanuatu on a path to eliminating cervical cancer.
Community health volunteers in Papua New Guinea will support a new cervical cancer elimination program in the Western Pacific.
A landmark $8.1 million investment from the Minderoo Foundation will support researchers from The Kirby Institute at UNSW Sydney to co-lead a new cervical cancer elimination program in the Western Pacific.
The initiative is co-led by the Cancer Council NSW, the Kirby Institute, VCS Foundation, and Family Planning NSW on behalf of the NHMRC Centre of Research Excellence in Cervical Cancer Control (C4), in close collaboration with in-country partners and stakeholders.
Major collaboration aims to eliminate cervical cancer in the Western Pacific
unsw.edu.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from unsw.edu.au Daily Mail and Mail on Sunday newspapers.
Cancer Council NSW and University of Sydney partner to enhance Australia s cancer research capacity
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
Boston, MA - Vaccinating adults age 26 and older against the human papillomavirus (HPV) the virus that causes more than 90% of cervical cancers as well as several other cancers may not be cost-effective, according to a new study led by researchers at the Harvard T.H. School of Public Health. Our study found that the added health benefit of increasing the vaccination age limit beyond 26 years is minimal, and that the cost-effectiveness is much lower than in pre-adolescents, the target age group for the HPV vaccine, said Jane Kim, K.T. Li Professor of Health Economics and lead author of the study.